SCHEMBL3517826

SCHEMBL3517826

COC(=O)c1c(OC)ccc2nc(-c3ccccc3)c(=O)[nH]c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
ERCC1 P07992 1/20 0.43
FEN1 P39748 1/20 0.43
ERCC4 Q92889 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
PTGS1 P23219 1/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 1/20 0.42
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518736 0.81 SMN1; SMN2 (0.45) SMN1; SMN2KDM4ENPC1RAB9AERCC1
SCHEMBL3518290 0.79 NPSR1 (0.49) DHODHSMN1; SMN2KDM4ENPSR1PTGS1
SCHEMBL3522740 0.75 DHODH (0.46) DHODHSMN1; SMN2KDM4ENPSR1PTGS1
SCHEMBL1458088 0.73 KDM4E (0.56) SMN1; SMN2KDM4ENPC1RAB9AALDH1A1
SCHEMBL3519204 0.72 PLA2G2A (0.45) DHODHSMN1; SMN2KDM4ENPC1NPSR1
SCHEMBL9960897 0.71 KDM4E (0.56) SMN1; SMN2KDM4ENPC1RAB9AALDH1A1
SCHEMBL1081897 0.69 DHODH (0.52) DHODHSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL10211229 0.69 KDM4E (0.50) SMN1; SMN2KDM4ENPC1RAB9AERCC1
SCHEMBL17184351 0.69 TP53 (0.45) SMN1; SMN2KDM4ENPC1RAB9ANPSR1
SCHEMBL3524998 0.68 ECE1 (0.52) DHODHKDM4ENPSR1PTGS1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 DHODH 20/4885SMN1; SMN2 3777/4885KDM4E 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.